Breast cancer cells were able to survive the harsh conditions of hypoxia by upregulating a glycolytic enzyme, 6-phosphofructo-2-kinase/fructose-2,6-biphosphatase-4 (PFKFB4), compared to the normoxic controls in vitro and in vivo (Dai et al., 2022). The gene discussed is PFKFB4; the disease is breast cancer.